Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies

NCT02743351 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT02743351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02743351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Lead sponsor
Fate Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
December 20, 2016
Completion date
November 5, 2021
Enrollment
96 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, hematologic malignancies, myelodysplastic syndromes